Nektar Therapeutics ended June with $1.02 billion in cash and investments, a figure that jumped from $245.8 million at year-end 2025 largely on the back of a $373.8 million equity offering completed in April. That balance matters because it buys time in a direct and measurable way: Nektar says the runway extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028. The structure of that runway is what makes this quarterly report worth reading beyond the financials.
The money is already flowing into the clinic. R&D expense rose to $39.1 million in Q2 2026 from $29.9 million in Q2 2025, driven by startup costs for the Phase 3 ZENITH AD program in atopic dermatitis and manufacturing scale-up for rezpegaldesleukin. Two of the three ZENITH AD trials launched in July. The program’s design is notable: ZENITH AD-1 and AD-2 enroll biologic and systemic JAK inhibitor treatment-naive patients, while ZENITH AD-3 targets patients with prior biologic or JAK inhibitor experience. That stratified enrollment reflects a crowded treatment landscape where dupilumab and approved JAK inhibitors have already carved distinct patient segments, and where any new entrant needs to demonstrate differentiated durability, not just response rates. Rezpegaldesleukin’s mechanism, regulatory T cell stimulation, is biologically distinct from IL-4/IL-13 blockade or kinase inhibition, which is precisely why the maintenance-phase data from the Phase 2b REZOLVE-AD study, scheduled for an oral presentation at EADV on October 1, will attract close attention from trial designers and payers alike.
The alopecia areata timeline adds another layer. Nektar plans a single registrational Phase 3 study in early 2027, and rezpegaldesleukin already holds FDA Fast Track designation for severe-to-very severe alopecia areata. The competitive clock is ticking: AbbVie has submitted an sNDA for upadacitinib in severe alopecia areata based on Phase 3 data, meaning any approved-therapy window is narrowing. Positive 52-week data from the REZOLVE-AA blinded extension, showing deepening responses with continued twice-monthly dosing, is a meaningful biological signal, but a single Phase 3 study will face intense regulatory scrutiny and will need to differentiate on durability and safety profile rather than novelty alone.
The number to track from here is the mid-2028 ZENITH AD interim readout. It determines whether the projected 2029 BLA submission stays on schedule, and whether the $1 billion in cash is actually sufficient to reach that inflection point without another dilutive raise.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
